|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Advanced Biotherapy Inc., of Woodland Hills, Calif., reported publication in the June issue of the American Journal of Ophthalmology of clinical data related to patients with half-transparent, edematous and cloudy corneal transplants. Anti-interferon-gamma fragments were administered three times a day for seven to 10 days. In 10 of 13 patients, two to three days after the start of treatment, transplant transparency improved, edema dropped and visual acuity increased from 0.2 to 0.3.
Argenta Discovery Ltd., of Harlow, UK, entered a drug discovery collaboration with Amedis Pharmaceuticals Ltd., of Cambridge, UK. Argenta will create a series of small-molecule ...